<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>BioWire</title>
	<atom:link href="http://biowire.bioscholar.com/feed" rel="self" type="application/rss+xml" />
	<link>http://biowire.bioscholar.com</link>
	<description></description>
	<lastBuildDate>Sun, 09 Jan 2011 14:23:07 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>KINAXO Enters Agreement with AstraZeneca</title>
		<link>http://biowire.bioscholar.com/2011/01/554.html</link>
		<comments>http://biowire.bioscholar.com/2011/01/554.html#comments</comments>
		<pubDate>Wed, 05 Jan 2011 14:14:41 +0000</pubDate>
		<dc:creator>pharmanews</dc:creator>
				<category><![CDATA[Merger & Acquisition]]></category>

		<guid isPermaLink="false">http://biowire.bioscholar.com/?p=554</guid>
		<description><![CDATA[Martinsried, Germany &#8211; KINAXO Biotechnologies GmbH announced today that it has entered into a collaboration with AstraZeneca. Under the terms of the agreement, KINAXO will apply its technology platform to support one of AstraZeneca’s oncology programs. KINAXO will employ high-end mass spectrometry-based technologies to quantitatively analyze posttranslational protein modifications on a proteome-wide scale. Since protein [...]]]></description>
		<wfw:commentRss>http://biowire.bioscholar.com/2011/01/554.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sartorius Appoints International Life Sciences Leader to its Top Management</title>
		<link>http://biowire.bioscholar.com/2011/01/556.html</link>
		<comments>http://biowire.bioscholar.com/2011/01/556.html#comments</comments>
		<pubDate>Mon, 03 Jan 2011 14:18:10 +0000</pubDate>
		<dc:creator>pharmanews</dc:creator>
				<category><![CDATA[Industry hires and promotions]]></category>

		<guid isPermaLink="false">http://biowire.bioscholar.com/?p=556</guid>
		<description><![CDATA[Goettingen, Germany – Effective January 1, 2011, the former Millipore executive, Dominique Baly, has assumed cross-divisional management of marketing, sales and service for the Sartorius laboratory business as President of Sartorius Group Laboratory Business. In this newly created position, he reports to the CEO and is a member of the Group Executive Committee. Sartorius Group [...]]]></description>
		<wfw:commentRss>http://biowire.bioscholar.com/2011/01/556.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biogen Idec and Neurimmune Announce Agreement on Three Neurodegenerative Disease Programs</title>
		<link>http://biowire.bioscholar.com/2010/12/559.html</link>
		<comments>http://biowire.bioscholar.com/2010/12/559.html#comments</comments>
		<pubDate>Tue, 21 Dec 2010 14:18:50 +0000</pubDate>
		<dc:creator>pharmanews</dc:creator>
				<category><![CDATA[Merger & Acquisition]]></category>

		<guid isPermaLink="false">http://biowire.bioscholar.com/?p=559</guid>
		<description><![CDATA[Biogen Idec (NASDAQ: BIIB) and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43. [...]]]></description>
		<wfw:commentRss>http://biowire.bioscholar.com/2010/12/559.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotage Announces an Easy, Cost-Effective Approach to the Analysis of Ethyl Glucuronide (EtG) in Urine</title>
		<link>http://biowire.bioscholar.com/2010/12/561.html</link>
		<comments>http://biowire.bioscholar.com/2010/12/561.html#comments</comments>
		<pubDate>Thu, 16 Dec 2010 14:20:01 +0000</pubDate>
		<dc:creator>pharmanews</dc:creator>
				<category><![CDATA[New Produtcs & Services]]></category>

		<guid isPermaLink="false">http://biowire.bioscholar.com/?p=561</guid>
		<description><![CDATA[Uppsala, Sweden – Biotage® (STO: BIOT), a leading supplier of tools and technology for analytical and medicinal chemistry, introduced a new sample preparation application note for the extraction of ethyl glucuronide from urine by LC-MS. EtG can be detected at very low levels and being a metabolite it is useful in distinguishing between ingested ethanol [...]]]></description>
		<wfw:commentRss>http://biowire.bioscholar.com/2010/12/561.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>HELM AG Acquires Shares in Amarin Technologies S.A.</title>
		<link>http://biowire.bioscholar.com/2010/12/564.html</link>
		<comments>http://biowire.bioscholar.com/2010/12/564.html#comments</comments>
		<pubDate>Wed, 15 Dec 2010 14:22:21 +0000</pubDate>
		<dc:creator>pharmanews</dc:creator>
				<category><![CDATA[Merger & Acquisition]]></category>

		<guid isPermaLink="false">http://biowire.bioscholar.com/?p=564</guid>
		<description><![CDATA[Effective September 28th, 2010, Hamburg based HELM AG has purchased a 30% shareholding in Amarin Technologies S.A. a privately owned pharmaceutical development company in Buenos Aires, Argentina. Amarin has more than 20 years of experience in the technology of transdermal delivery systems and owns several patents. The mid-size company has been cooperating with HELM successfully [...]]]></description>
		<wfw:commentRss>http://biowire.bioscholar.com/2010/12/564.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gene Logic announces appointment of Norrie Russell as President</title>
		<link>http://biowire.bioscholar.com/2010/09/547.html</link>
		<comments>http://biowire.bioscholar.com/2010/09/547.html#comments</comments>
		<pubDate>Mon, 06 Sep 2010 01:28:29 +0000</pubDate>
		<dc:creator>pharmanews</dc:creator>
				<category><![CDATA[Industry hires and promotions]]></category>

		<guid isPermaLink="false">http://biowire.bioscholar.com/?p=547</guid>
		<description><![CDATA[Gene Logic, an Ocimum Biosolutions company, a leading provider of genomic solutions, is pleased to announce the appointment of Norrie J. W. Russell, Ph. D., as the President of the company. With more than 30 years of experience in drug discovery, Dr. Russell has a long history of success driving innovation in pharmaceutical discovery and [...]]]></description>
		<wfw:commentRss>http://biowire.bioscholar.com/2010/09/547.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mucosis Receives Financial Support from the Dutch Government</title>
		<link>http://biowire.bioscholar.com/2010/05/532.html</link>
		<comments>http://biowire.bioscholar.com/2010/05/532.html#comments</comments>
		<pubDate>Mon, 31 May 2010 14:37:17 +0000</pubDate>
		<dc:creator>pharmanews</dc:creator>
				<category><![CDATA[Biotech/Pharma Business]]></category>

		<guid isPermaLink="false">http://biowire.bioscholar.com/?p=532</guid>
		<description><![CDATA[Dutch vaccine development company Mucosis B.V. announced today that it has received an innovation credit line of approximately € 3 million from Agentschap NL, an agency of the Dutch Ministry of Economic Affairs. Mucosis will use this loan towards the clinical development of its lead product FluGEM™, an influenza vaccine that can be administered by [...]]]></description>
		<wfw:commentRss>http://biowire.bioscholar.com/2010/05/532.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ubichem Approved for cGMP Radiolabelled API Production</title>
		<link>http://biowire.bioscholar.com/2010/05/530.html</link>
		<comments>http://biowire.bioscholar.com/2010/05/530.html#comments</comments>
		<pubDate>Mon, 31 May 2010 14:35:47 +0000</pubDate>
		<dc:creator>pharmanews</dc:creator>
				<category><![CDATA[Regulatory Affairs]]></category>

		<guid isPermaLink="false">http://biowire.bioscholar.com/?p=530</guid>
		<description><![CDATA[Ubichem, a leading provider of chemistry services to the drug development sector, through its Hungarian operation – Ubichem Research &#8211; has successfully completed a regulatory inspection and is now approved for the supply of cGMP radiolabelled Active Pharmaceutical Ingredients (APIs). Jozsef Repasi, Managing Director of Ubichem Research commented: “This approval enables us to supply radiolabelled [...]]]></description>
		<wfw:commentRss>http://biowire.bioscholar.com/2010/05/530.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Preclinical data shows Restanza to be effective against gonorrhea</title>
		<link>http://biowire.bioscholar.com/2010/05/540.html</link>
		<comments>http://biowire.bioscholar.com/2010/05/540.html#comments</comments>
		<pubDate>Fri, 28 May 2010 14:55:16 +0000</pubDate>
		<dc:creator>pharmanews</dc:creator>
				<category><![CDATA[Clinical Trials]]></category>

		<guid isPermaLink="false">http://biowire.bioscholar.com/?p=540</guid>
		<description><![CDATA[Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the expansion of its collaboration with the U.S. Government to include the evaluation of Restanza&#8217;s activity against sexually transmitted infections (STI&#8217;s), such as gonorrhea. Under [...]]]></description>
		<wfw:commentRss>http://biowire.bioscholar.com/2010/05/540.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>VaxGen to Acquire diaDexus</title>
		<link>http://biowire.bioscholar.com/2010/05/538.html</link>
		<comments>http://biowire.bioscholar.com/2010/05/538.html#comments</comments>
		<pubDate>Fri, 28 May 2010 14:53:27 +0000</pubDate>
		<dc:creator>pharmanews</dc:creator>
				<category><![CDATA[Merger & Acquisition]]></category>

		<guid isPermaLink="false">http://biowire.bioscholar.com/?p=538</guid>
		<description><![CDATA[VaxGen, Inc. , a biopharmaceutical company, and diaDexus, Inc., a privately held diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, announced today that they have entered into a definitive agreement under which VaxGen will acquire diaDexus in a stock-for-stock merger. In connection with [...]]]></description>
		<wfw:commentRss>http://biowire.bioscholar.com/2010/05/538.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

